Goldman Sachs
RAPP

Goldman Sachs’s Rapport Therapeutics RAPP Stock Holding History

Goldman Sachs’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$121M Sell
2,910,449
-31,802
-1% -$1.17M 0.01% 1095
2026
Q1 		$92.1M Sell
2,942,251
-59,628
-2% -$1.68M 0.01% 1084
2025
Q4 		$91.1M Buy
3,001,879
+579,903
+24% +$16M 0.01% 1057
2025
Q3 		$71.9M Buy
2,421,976
+1,186,941
+96% +$21.2M 0.01% 1153
2025
Q2 		$14M Sell
1,235,035
-9,275
-0.7% -$98.4K ﹤0.01% 2442
2025
Q1 		$12.5M Sell
1,244,310
-7,826
-0.6% -$102K ﹤0.01% 2477
2024
Q4 		$22.2M Buy
1,252,136
+4,965
+0.4% +$110K ﹤0.01% 2026
2024
Q3 		$25.5M Buy
+1,247,171
New +$26.8M ﹤0.01% 1822

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Goldman Sachs's RAPP Position: Q2 2026 in Review

Goldman Sachs reduced its Rapport Therapeutics (RAPP) stake by 1.1% in Q2 2026, selling an estimated $1.17M and leaving 2,910,449 shares worth $121M. The position accounts for 0.01% of the portfolio, ranked #1095.

Goldman Sachs first reported a position in RAPP in Q3 2024 and has held it in 8 quarters since. 160 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • Goldman Sachs held 2,910,449 shares of Rapport Therapeutics worth $121M as of Q2 2026.
  • Goldman Sachs sold 31,802 Rapport Therapeutics shares in Q2 2026, an estimated $1.17M.
  • Rapport Therapeutics made up 0.01% of Goldman Sachs's portfolio in Q2 2026, its #1095 holding.
  • Goldman Sachs first reported a position in Rapport Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 160 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.